Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887862 | 0.90 | MEN1 (0.48) | ATMPIK3CDPDCD1CD274MEN1 | |
| SCHEMBL1887556 | 0.90 | PIK3CD (0.53) | ATMPIK3CDMEN1KMT2ADRD4 | |
| SCHEMBL1879925 | 0.88 | ATM (0.51) | ATMPIK3CDDRD4DRD3L3MBTL1 | |
| SCHEMBL1598116 | 0.85 | PIK3CD (0.49) | ATMPIK3CDMEN1KMT2A | |
| SCHEMBL1888310 | 0.85 | PIK3CD (0.54) | ATMPIK3CDMEN1KMT2A | |
| SCHEMBL1886097 | 0.85 | PIK3CD (0.64) | ATMPIK3CDMEN1KMT2ADRD4 | |
| SCHEMBL1879384 | 0.83 | ATM (0.49) | ATMPIK3CDMEN1KMT2A | |
| SCHEMBL4173906 | 0.83 | PIK3CD (0.58) | ATMPIK3CDPDCD1CD274 | |
| SCHEMBL1886286 | 0.82 | PIK3CD (0.54) | ATMPIK3CDMEN1KMT2ADRD4 | |
| SCHEMBL1598353 | 0.82 | PIK3CD (0.57) | ATMPIK3CDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2015-02-12 | — | — | US | disclosed |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2015-02-12 | — | — | US | disclosed |
| US-8901135-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ATM 750/4885PIK3CD 16/4885PDCD1 495/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | ATM 750/4885PIK3CD 16/4885PDCD1 495/4885 |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ATM 750/4885PIK3CD 16/4885PDCD1 495/4885 |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ATM 750/4885PIK3CD 16/4885PDCD1 495/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ATM 750/4885PIK3CD 16/4885PDCD1 495/4885 |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ATM 750/4885PIK3CD 16/4885PDCD1 495/4885 |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | ATM 545/4885PIK3CD 8/4885PDCD1 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.